Yung Shin Pharmaceutical Ind. Co., Ltd.

Yung Shin Pharm. Ind. Co., Ltd.

Yung Shin Pharmaceutical Industrial Co. Ltd.

Carlsbad Technology, Inc.

Fang Yu Lee

Sheng-Chu Kuo

Che-Ming Teng

Shiow-Lin Pan

Jih-Hwa Guh

Tsang-Miao Huang

Xu Wu

Chao-Ho Chung

Wu Qiu Ye

Xiao Xu Hua

Fang Chen Lee

Chang An Yang

Ma Wei Yong

A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar, Ar, and Ar, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R, R, R, R, R, and R, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR', (CH)OR, (CH)SR, (CH)NRR&#x2032;, (CH)CN, (CH)C(O)OR, (CH)CHO, (CH)CH&#x2550;NOR, or Rand Rtogether, Rand Rtogether, or Rand Rtogether are O(CH)O, in which each of R and R&#x2032;, independently, is H or C&#x2dc;Calkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.

Angiogenesis inhibitors

Fused tri-heterocyclic compounds of formula:Ris H or alkyl; Ris H, alkyl, alkenyl, aryl, heteroaryl, cyclyl, or heterocyclyl; Rand R, independently, is H, alkyl, alkenyl, aryl, heteroaryl, cyclyl, heterocyclyl, or (CRR)X(CRR)Y; in which X is a bond, O, S, or NR; Y is alkoxy, aryloxy, heteroaryloxy, OC(O)R, C(O)R, N(RR), NRC(O)R, S(O)R, or SR; each of m and n, independently, is 1, 2, 3, 4, or 5; each of R, R, R, R, R, and R, independently, is H, alkyl, aryl, heteroaryl, cyclyl, or heterocyclyl; and Ris H or halogen.

9H-imidazo[1,2-a]purin-9-one compounds

Pharmaceutically acceptable salt of amlodipine and method of preparing the same

Fused pyrazolyl compounds

A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

Method of treating disorders related to protease-activated receptors-induced cell activation

The invention pertains to a process for preparing (1-substituted benzyl)-3-(hydroxy-carbonyl aryl) condensed pyrazoles or (1-substituted benzyl)-3-(hydroxymethyl aryl) condensed pyrazoles comprising the steps of: (a) reacting compound I and compound II, or compound III and compound IV, to produce compound V, which is a substituted aryl ketone, as follows: ##STR1## wherein Ar.sub.2 and At.sub.3 can be, independently, ##STR2## R.sub.1 is H, C.sub.1-3 alkyl, or X (halogen), R.sub.3 is H, C.sub.1-3 alkyl, X (halogen), or --OR radical, and R is H or C.sub.1-3 alkyl; the process comprising the following steps of: R.sub.2 represents CH.sub.2 OR, H, COOR, C.sub.1-3 alkyl, or X (halogen); (b) reacting the compound V with a hydrazine compound to form a hydrazone compound; (c) reacting the hydrazone compound compound with trifluoride etherate (BF.sub.3 .cndot.Et.sub.2 O) to form a 1-(substituted benzyl) 3-(substituted aryl) condensed pyraxzole, which is represented by the following formula of ##STR3## Compound X can be further hydrolyzed or reduced to form corresponding carboxylic acids or alcohols.

1-(substituted benzyl)-3-(substituted aryl)-condensed pyrazole

Growing community of inventors

Taichung, Taiwan

Fang Yu Lee